5个月大的患者因特应性皮炎导致生长发育迟缓及高钠血症性脱水，使用度普利尤单抗进行治疗。 - Suppr

Suppr

超能文献

Atopic dermatitis-induced failure to thrive and hypernatremic dehydration managed with dupilumab in a 5-month-old patient.

作者信息

Walterscheid Brooke, Fenner Blayne, Chaudhury Hannah, Tarbox Michelle

机构信息

Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas.

Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.

出版信息

JAAD Case Rep. 2025 Mar 24;60:30-33. doi: 10.1016/j.jdcr.2024.10.042. eCollection 2025 Jun.

DOI:10.1016/j.jdcr.2024.10.042

PMID:40353095

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12063005/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/077a/12063005/2529bac065fb/gr1.jpg

相似文献

Atopic dermatitis-induced failure to thrive and hypernatremic dehydration managed with dupilumab in a 5-month-old patient.5个月大的患者因特应性皮炎导致生长发育迟缓及高钠血症性脱水，使用度普利尤单抗进行治疗。

JAAD Case Rep. 2025 Mar 24;60:30-33. doi: 10.1016/j.jdcr.2024.10.042. eCollection 2025 Jun.

Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.儿童中重度特应性皮炎患者接受度普利尤单抗治疗后出现银屑病样皮炎。

Pediatr Dermatol. 2021 Nov;38(6):1500-1505. doi: 10.1111/pde.14820. Epub 2021 Oct 14.

Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?度普利尤单抗治疗特应性皮炎：我们一直在寻找的万灵药？

Cureus. 2020 Apr 6;12(4):e7565. doi: 10.7759/cureus.7565.

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.度普利尤单抗为中度至重度特应性皮炎成人患者提供快速且持续的具有临床意义的缓解。

Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307.

Severe atopic dermatitis treated with Dupilumab in a CTLA-4-deficient patient: A case report and review of the literature.在一名CTLA-4缺陷患者中使用度普利尤单抗治疗重度特应性皮炎：病例报告及文献复习

SAGE Open Med Case Rep. 2025 Jan 7;13:2050313X241311042. doi: 10.1177/2050313X241311042. eCollection 2025.

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.度普利尤单抗治疗特应性皮炎患者的长期疗效：RELIEVE-AD研究3年随访结果

Dermatol Ther (Heidelb). 2023 Sep;13(9):2107-2120. doi: 10.1007/s13555-023-00965-5. Epub 2023 Aug 8.

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.度普利尤单抗治疗可使成人特应性皮炎患者的症状和生活质量在两年内持续改善。

Dermatol Ther (Heidelb). 2021 Dec;11(6):2147-2157. doi: 10.1007/s13555-021-00630-9. Epub 2021 Oct 29.

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.一项前瞻性观察性队列研究比较了环孢素、度普利尤单抗和甲氨蝶呤在成人和儿童特应性皮炎患者中的治疗效果和安全性：来自英国-爱尔兰 A-STAR 登记处的结果。

Br J Dermatol. 2024 Nov 18;191(6):988-999. doi: 10.1093/bjd/ljae287.

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.阿泊替尼治疗重度和/或难治性特应性皮炎患者的疗效和安全性：随机 3 期 JADE COMPARE 试验的事后分析。

Am J Clin Dermatol. 2023 Jul;24(4):609-621. doi: 10.1007/s40257-023-00785-5. Epub 2023 May 22.

Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study.度普利尤单抗治疗特应性皮炎患者的性功能和睡眠质量改善：一项单中心前瞻性观察研究。

Int J Environ Res Public Health. 2023 Jan 20;20(3):1918. doi: 10.3390/ijerph20031918.

本文引用的文献

Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.度普利尤单抗通过抑制 Th2 介导的炎症改善 Netherton 综合征患儿的临床症状。

Front Immunol. 2022 Dec 8;13:1054422. doi: 10.3389/fimmu.2022.1054422. eCollection 2022.

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.一项为期 16 周的随机 III 期研究：度普利尤单抗对 6 个月至 5 岁中重度特应性皮炎儿童的实验室安全性。

Paediatr Drugs. 2023 Jan;25(1):67-77. doi: 10.1007/s40272-022-00553-8. Epub 2022 Dec 19.

Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting.特应性皮炎的最新进展和研究进展：重点关注儿科环境中的流行病学、发病机制和治疗。

Paediatr Drugs. 2022 Jul;24(4):293-305. doi: 10.1007/s40272-022-00499-x. Epub 2022 Jun 13.

Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.5 月龄重症特应性皮炎婴儿使用度普利尤单抗的安全性。

Pediatr Dermatol. 2022 Mar;39(2):291-294. doi: 10.1111/pde.14980.

Hyponatremia secondary to severe atopic dermatitis in early infancy.婴儿早期严重特应性皮炎继发低钠血症。

Pediatr Int. 2019 Jun;61(6):544-550. doi: 10.1111/ped.13865. Epub 2019 Jun 18.

Hyperaldosteronemia and hypogammaglobulinemia secondary to atopic dermatitis-induced exudation in an infant presenting with growth failure.

Tokai J Exp Clin Med. 2007 Mar 20;32(1):18-22.

Hypoproteinemia in severe childhood atopic dermatitis: a serious complication.重度儿童特应性皮炎中的低蛋白血症：一种严重并发症。

Pediatr Allergy Immunol. 2002 Aug;13(4):287-94. doi: 10.1034/j.1399-3038.2002.01041.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验